Nippon Kayaku Co.,Ltd.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Tokyo Japan (1916)
Status: No NME R&D (1916)

Organization Overview

First Clinical Trial
2003
NCT00709722
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (3)

apaziquone (1 trial)

paclitaxel (taxol) (1 trial)

trastuzumab (herceptin) (1 trial)

Drugs in Phase 2 Trials (2)

gusperimus (3 trials)

sn-38 (5 trials)

Drugs in Phase 1 Trials (2)

carboplatin (paraplatin) (1 trial)

fluorouracil (efudex) (1 trial)

Drugs in Other Trials (1)

cetrorelix (cetrotide) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 3)

Colorectal Neoplasms (Phase 1)

Granulomatosis with Polyangiitis (Phase 2)

Lung Neoplasms (Phase 2)

Lupus Nephritis (Phase 2)

Nephritis (Phase 2)

Small Cell Lung Carcinoma (Phase 2)

Triple Negative Breast Neoplasms (Phase 2)

Urinary Bladder Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 12
  • # of Trial APIs: 8